IN2013MU01208A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MU01208A IN2013MU01208A IN1208MU2013A IN2013MU01208A IN 2013MU01208 A IN2013MU01208 A IN 2013MU01208A IN 1208MU2013 A IN1208MU2013 A IN 1208MU2013A IN 2013MU01208 A IN2013MU01208 A IN 2013MU01208A
- Authority
- IN
- India
- Prior art keywords
- present
- xanthophylls
- composition
- zeaxanthin
- neurodegenerative disorders
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 3
- 235000008210 xanthophylls Nutrition 0.000 abstract 3
- 235000021466 carotenoid Nutrition 0.000 abstract 2
- 150000001747 carotenoids Chemical class 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 150000003735 xanthophylls Chemical class 0.000 abstract 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 235000012680 lutein Nutrition 0.000 abstract 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 1
- JKQXZKUSFCKOGQ-YOPUJPICSA-N meso-zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@H](O)CC1(C)C JKQXZKUSFCKOGQ-YOPUJPICSA-N 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 239000008601 oleoresin Substances 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- -1 xanthophylls esters Chemical class 0.000 abstract 1
- 239000001775 zeaxanthin Substances 0.000 abstract 1
- 229940043269 zeaxanthin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides use of composition containing molecular dispersions of carotenoids for the prevention of neurodegenerative disorders which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits. The present invention particularly relates to the use of highly water soluble composition with enhanced bioavailability containing at least 80% by weight of total xanthophylls, out of which the trans-lutein content is 80-95% w/w; (R,R)-zeaxanthin is 14-20% w/w; (R,S)-zeaxanthin is 0.01-1% w/w and traces of other carotenoids derived from the plant extracts/oleoresin containing xanthophylls/xanthophylls esters. The present invention also provides use of the said composition in treatment of neurodegenerative disorders when co-administered along with reduced dose of Levodopa and Carbidopa.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201480019000.4A CN105120853A (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| EP14722714.4A EP2978418A1 (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| AU2014242655A AU2014242655A1 (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| PCT/IB2014/000447 WO2014155189A1 (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| JP2016504769A JP2016520540A (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effects of carotenoids in the brain |
| US14/780,595 US9849096B2 (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| IN1208MU2013 IN2013MU01208A (en) | 2013-03-28 | 2014-03-28 | |
| MX2015013624A MX2015013624A (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain. |
| SG11201507973TA SG11201507973TA (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| CA2907886A CA2907886A1 (en) | 2013-03-28 | 2014-03-28 | Neuroprotective effect of carotenoids in brain |
| PH12015502238A PH12015502238A1 (en) | 2013-03-28 | 2015-09-24 | Neuroprotective effect of carotenoids in brain |
| HK15112649.3A HK1211836A1 (en) | 2013-03-28 | 2015-12-23 | Neuroprotective effect of carotenoids in brain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1208MU2013 IN2013MU01208A (en) | 2013-03-28 | 2014-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MU01208A true IN2013MU01208A (en) | 2015-07-03 |
Family
ID=50685962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1208MU2013 IN2013MU01208A (en) | 2013-03-28 | 2014-03-28 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9849096B2 (en) |
| EP (1) | EP2978418A1 (en) |
| JP (1) | JP2016520540A (en) |
| CN (1) | CN105120853A (en) |
| AU (1) | AU2014242655A1 (en) |
| CA (1) | CA2907886A1 (en) |
| HK (1) | HK1211836A1 (en) |
| IN (1) | IN2013MU01208A (en) |
| MX (1) | MX2015013624A (en) |
| PH (1) | PH12015502238A1 (en) |
| SG (1) | SG11201507973TA (en) |
| WO (1) | WO2014155189A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145389A2 (en) * | 2014-03-28 | 2015-10-01 | Omniactive Health Technologies Limited | Effect of lipophilic nutrients on diabetic eye diseases |
| EP3265068A4 (en) | 2015-03-02 | 2018-10-31 | OmniActive Health Technologies Limited | Method for protection and improvement of liver health with meso-zeaxanthin compositions |
| US10583095B2 (en) | 2015-03-02 | 2020-03-10 | Omniactive Health Technologies Limited | Method for stress management and overall health status improvement and compositions used therein |
| US20190314442A1 (en) * | 2016-02-22 | 2019-10-17 | Newtricious B.V. | Composition for the prevention or treatment of neurodegenerative diseases |
| EP3632418A4 (en) * | 2017-06-01 | 2021-02-24 | Santen Pharmaceutical Co., Ltd. | Brain-dysfunction preventing and/or improving composition containing lutein or salt thereof and processed product of plant belonging to genust |
| GB201720119D0 (en) * | 2017-12-04 | 2018-01-17 | Howard Foundation Holdings Ltd | Prevention and/or treatment of neurodegenerative disease |
| GB201801985D0 (en) * | 2018-02-07 | 2018-03-28 | Ip Science Ltd | Formulation of carotenoids |
| CA3095341A1 (en) * | 2018-03-29 | 2019-10-03 | Avion Pharmaceuticals, Llc | Levodopa fractionated dose composition and use |
| SG10201900604TA (en) * | 2019-01-23 | 2020-08-28 | Agency For Science Technology And Research Astarstar | Pre-natal beta-cryptoxanthin benefits children |
| FR3092968B1 (en) * | 2019-02-22 | 2021-05-21 | Microphyt | DIETARY SUPPLEMENT |
| FR3117339A1 (en) | 2020-12-16 | 2022-06-17 | Naos Institute Of Life Science | Use of bacterioruberins and their glycosylated derivatives to prevent and treat diseases involving deregulation of protein aggregation, such as neurodegenerative diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ220599A (en) * | 1986-06-16 | 1990-10-26 | Merck & Co Inc | Controlled release oral dosage formulation of carbidopa and levodopa |
| IL110139A0 (en) | 1993-06-28 | 1994-10-07 | Howard Foundation | Pharmaceutically-active antioxidants |
| DE19609477A1 (en) | 1996-03-11 | 1997-09-18 | Basf Ag | Stable aqueous solubilisates of carotenoids and vitamins |
| US7081478B2 (en) | 2001-06-29 | 2006-07-25 | Chrysantis, Inc. | Mixed zeaxanthin ester concentrate and uses thereof |
| US20060205826A1 (en) * | 2005-03-09 | 2006-09-14 | Romero Francisco J | Method of using carotenoids in the prevention of cognitive decline and for other neuroprotection functions |
| US20070238793A1 (en) | 2005-12-07 | 2007-10-11 | Lockwood Samuel F | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status |
| WO2008099469A1 (en) | 2007-02-14 | 2008-08-21 | Tohoku University | Composition and method for suppressing lipid peroxidation in erythrocytes |
| PT2473065E (en) * | 2009-09-02 | 2016-06-03 | Omniactive Health Tech Ltd | A xanthophyl composition containing macular pigments and a process for its preparation |
| CN102210662A (en) | 2010-04-06 | 2011-10-12 | 北京联合大学应用文理学院 | Application of lutein in preparation of medicaments for preventing and treating cerebral vascular diseases |
-
2014
- 2014-03-28 CN CN201480019000.4A patent/CN105120853A/en active Pending
- 2014-03-28 SG SG11201507973TA patent/SG11201507973TA/en unknown
- 2014-03-28 CA CA2907886A patent/CA2907886A1/en not_active Abandoned
- 2014-03-28 US US14/780,595 patent/US9849096B2/en active Active
- 2014-03-28 JP JP2016504769A patent/JP2016520540A/en active Pending
- 2014-03-28 WO PCT/IB2014/000447 patent/WO2014155189A1/en active Application Filing
- 2014-03-28 EP EP14722714.4A patent/EP2978418A1/en not_active Withdrawn
- 2014-03-28 IN IN1208MU2013 patent/IN2013MU01208A/en unknown
- 2014-03-28 AU AU2014242655A patent/AU2014242655A1/en not_active Abandoned
- 2014-03-28 MX MX2015013624A patent/MX2015013624A/en unknown
-
2015
- 2015-09-24 PH PH12015502238A patent/PH12015502238A1/en unknown
- 2015-12-23 HK HK15112649.3A patent/HK1211836A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9849096B2 (en) | 2017-12-26 |
| WO2014155189A1 (en) | 2014-10-02 |
| EP2978418A1 (en) | 2016-02-03 |
| US20160051490A1 (en) | 2016-02-25 |
| AU2014242655A1 (en) | 2015-10-22 |
| CA2907886A1 (en) | 2014-10-02 |
| SG11201507973TA (en) | 2015-10-29 |
| JP2016520540A (en) | 2016-07-14 |
| CN105120853A (en) | 2015-12-02 |
| HK1211836A1 (en) | 2016-06-03 |
| PH12015502238A1 (en) | 2016-02-01 |
| MX2015013624A (en) | 2016-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2013MU01208A (en) | ||
| BR112017012299A2 (en) | immune modulation | |
| MX2017008813A (en) | Beetle powder. | |
| PH12014502336A1 (en) | Iron supplementation of rice kernels | |
| EP3318262A3 (en) | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease | |
| IN2014MU01128A (en) | ||
| NZ702977A (en) | 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof | |
| MX2017008815A (en) | Composition containing chitin and digestible proteins. | |
| GB201210699D0 (en) | Nutritional food | |
| MX2015015628A (en) | Tall oil fatty acid for use in treatment and animal feed supplements and compositions. | |
| WO2013028555A3 (en) | Methods for weight loss and ketogenic compositions | |
| MX2014004507A (en) | Novel coating system. | |
| WO2013049519A3 (en) | Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols | |
| EA033540B1 (en) | Composition comprising okra for use in reducing dietary fat absorption | |
| WO2016190682A3 (en) | Composition for preventing and treating muscle diseases or improving muscular function, containing morusin, kuwanon g, or mori cortex radicis | |
| MX2016016995A (en) | Composition containing phytic acid, magnesium and polyphenols for the treatment or prevention of renal lithiasis. | |
| PH12017500706A1 (en) | Composition containing extract or fraction of genus justicia plant | |
| MX2016012427A (en) | Nutritional supplement powder. | |
| MX2013004371A (en) | Cysteine and food intake. | |
| PH12017500203B1 (en) | Nutritional composition for use in promoting gut and/or liver maturation and/or repair | |
| PH12016500914A1 (en) | Nutrition, exercise and cognitive development | |
| MX349208B (en) | Use of caftaric acid and derivatives in food supplement for regulating skin pigmentation. | |
| WO2011089525A3 (en) | Chia seed protein concentrate | |
| NZ738591A (en) | Concentrated fruit juice for a marinade | |
| MX2020009629A (en) | A composition for use in the treatment of conditions caused by calcium deficiency. |